Cancer drug shortages should be causing more outrage скачать в хорошем качестве

Cancer drug shortages should be causing more outrage

Drug shortages are a growing problem in the U.S., and a shortage of livesaving cancer drugs in particular has reached crisis levels. On the latest episode of the “First Opinion Podcast,” oncologist Kristen Rice explains that drug shortages have been happening for several years but have been progressively worsening in the past few months. Oncologists are facing critical shortages of common, generic cancer medications and have even begun to ration care for certain patients who are able to delay treatment, according to Rice. “Patients are already under a lot of stress — they’re dealing with a cancer diagnosis, and they’re terrified. The last thing they want to hear is that something that’s critical to controlling their cancer might not be available, and we’re wondering where the next dose is going to come from,” Rice said. The conversation is based off Rice’s recent First Opinion, “Cancer drug shortages should have patients rioting in the streets." More from STAT: Become a subscriber: https://www.statnews.com/stat-plus/ Watch Full Episodes: / @statnews Newsletters: https://www.statnews.com/signup/ STAT events: https://www.statnews.com/stat-events/ Facebook:   / statnews   Twitter:   / statnews   Instagram:   / statnews   Flipboard: rb.gy/3xnsxr STAT Reports: https://rb.gy/rexfwj STAT eBooks: https://rb.gy/eme3h5 ABOUT STAT: Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health.